Loading...
OTCMEKTAY
Market cap2.01bUSD
Dec 24, Last price  
5.25USD
1D
-3.85%
1Q
-21.41%
Jan 2017
-39.52%
Name

Elekta AB (publ)

Chart & Performance

D1W1MN
OTCM:EKTAY chart
P/E
16.41
P/S
1.18
EPS
3.55
Div Yield, %
47.58%
Shrs. gr., 5y
—
Rev. gr., 5y
5.98%
Revenues
18.12b
+7.41%
3,152,000,0004,421,000,0004,525,000,0005,081,000,0006,689,000,0007,392,000,0007,904,000,0009,048,000,00010,339,000,00010,694,000,00010,839,000,00011,221,000,00010,704,000,00011,333,000,00013,555,000,00014,601,000,00013,763,000,00014,548,000,00016,869,000,00018,119,000,000
Net income
1.30b
+38.07%
253,000,000304,000,000348,000,000406,000,000546,000,000833,000,0001,031,000,0001,227,000,0001,340,000,0001,148,000,000552,000,000137,000,000125,000,0001,099,000,0001,198,000,0001,084,000,0001,254,000,0001,154,000,000943,000,0001,302,000,000
CFO
2.46b
+25.31%
408,000,000498,000,000150,000,000319,000,000740,000,0001,056,000,000840,000,000635,000,0001,870,000,0001,275,000,0001,823,000,0001,170,000,0001,819,000,0002,404,000,0001,621,000,0001,014,000,0002,551,000,0001,858,000,0001,964,000,0002,461,000,000
Dividend
Sep 09, 20240.01116414 USD/sh
Earnings
Feb 21, 2025

Profile

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
URL
https://www.elekta.com/
IPO date
Mar 01, 1994
Employees
4,700
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑042015‑04
Income
Revenues
18,119,000
7.41%
16,869,000
15.95%
14,548,000
5.70%
Cost of revenue
15,757,000
14,939,000
13,011,000
Unusual Expense (Income)
NOPBT
2,362,000
1,930,000
1,537,000
NOPBT Margin
13.04%
11.44%
10.57%
Operating Taxes
365,000
254,000
345,000
Tax Rate
15.45%
13.16%
22.45%
NOPAT
1,997,000
1,676,000
1,192,000
Net income
1,302,000
38.07%
943,000
-18.28%
1,154,000
-7.97%
Dividends
(917,000)
(917,000)
(841,000)
Dividend yield
3.03%
2.79%
3.30%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,346,000
250,000
755,000
Long-term debt
7,221,000
7,366,000
6,026,000
Deferred revenue
237,000
215,000
Other long-term liabilities
319,000
41,000
120,000
Net debt
5,788,000
4,319,000
3,672,000
Cash flow
Cash from operating activities
2,461,000
1,964,000
1,858,000
CAPEX
(1,644,000)
(1,564,000)
(1,408,000)
Cash from investing activities
(1,923,000)
(1,615,000)
(1,649,000)
Cash from financing activities
(1,099,000)
(129,000)
(1,726,000)
FCF
1,526,000
1,851,000
1,112,000
Balance
Cash
2,779,000
3,270,000
3,069,000
Long term investments
27,000
40,000
Excess cash
1,873,050
2,453,550
2,381,600
Stockholders' equity
9,967,000
8,921,000
8,103,000
Invested Capital
16,473,950
13,610,450
12,103,400
ROIC
13.28%
13.04%
10.63%
ROCE
12.59%
11.67%
10.22%
EV
Common stock shares outstanding
382,086
382,367
382,083
Price
79.20
-7.97%
86.06
28.95%
66.74
-41.09%
Market cap
30,261,211
-8.04%
32,906,504
29.04%
25,500,227
-41.09%
EV
36,054,211
37,229,504
29,175,227
EBITDA
3,498,000
2,992,000
2,576,000
EV/EBITDA
10.31
12.44
11.33
Interest
482,000
226,000
148,000
Interest/NOPBT
20.41%
11.71%
9.63%